Thyroid Transcription Factor-1 Amplification and Expressions in Lung Adenocarcinoma Tissues and Pleural Effusions Predict Patient Survival and Prognosis

被引:38
|
作者
Li, Xiao [2 ]
Wan, Liyan [3 ]
Shen, Hong [3 ]
Geng, Jian [3 ]
Nie, Jing [1 ]
Wang, Guobao [1 ]
Jia, Nan [1 ]
Dai, Meng [4 ]
Bai, Xiaoyan [1 ]
机构
[1] So Med Univ, Nanfang Hosp, Guangdong Prov Inst Nephrol, Guangzhou 510515, Guangdong, Peoples R China
[2] So Med Univ, Nanfang Hosp, Dept Emergency, Guangzhou 510515, Guangdong, Peoples R China
[3] So Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China
[4] So Med Univ, Nanfang Hosp, Hlth Management Ctr, Guangzhou 510515, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Lung adenocarcinoma; TTF1; FISH; MPE; Survival; GENE AMPLIFICATION; CANCER; TTF-1; ASSOCIATION; MICROARRAYS; CARCINOMA;
D O I
10.1097/JTO.0b013e318232b98a
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Thyroid transcription factor-1 (TTF1) plays a role in lung adenocarcinoma development. We investigated the significance of TTF1 in primary lung adenocarcinomas, lymph node metastases, and malignant pleural effusions (MPEs). Methods: We studied TTF1 in 175 primary lung adenocarcinomas, 52 lymph node metastases, and 46 MPE using microarray-based fluorescence in situ hybridization, immunohistochemistry, and messenger RNA (mRNA) in situ hybridization. Real-time reverse transcription polymerase chain reaction was used to investigate correlations between TTF1 amplification and mRNA expression. Correlations between clinicopathologic characteristics, TTF1 amplification, TTF1 expressions, overall survival, and prognosis were analyzed. Results: TTF1 was amplified in 7% of primary lung adenocarcinomas, 4% of lymph node metastases, and 4% of MPE. TTF1 amplification in lung adenocarcinomas was associated with pathologic subtypes (p = 0.029). Patients with positive TTF1 protein and mRNA expressions had improved overall survival if TTF1 was unamplified compared with those with TTF1 amplification (p = 0.068). A multivariate model did not show patients with positive TTF1 expressions tended to have better prognoses if TTF1 was unamplified compared with those with TTF1 amplification (p = 0.068). Survival time was longer for patients with TTF1 expressions in both primary lung tissues (p < 0.001) and MPE (p = 0.045). A multivariate model confirmed the prognostic value of TTF1 expressions in lung adenocarcinoma (p < 0.001). A multivariate model confirmed the prognostic value of TTF1 experssions in lung adenocarcinoma tissues (p < 0.001) while not in MPE (p = 0.058). TTF1 mRNA level was higher in cases with TTF1 amplification compared with those without TTF1 amplification. Conclusions: Patients with lung adenocarcinoma without TTF1 amplification tend to have better prognoses than those with TTF1 amplification in cases with positive TTF1 expressions. Positive TTF1 expressions in lung adenocarcinoma tissues are favorable prognostic parameters in patients with lung adenocarcinoma.
引用
收藏
页码:76 / 84
页数:9
相关论文
共 50 条
  • [41] Downregulation of Thyroid transcription factor 1 in lung adenocarcinoma: the prognostic impact
    Caires, Nidia Pestana
    Castanho, Margarida
    Hasmucrai, Direndra
    Teixeira, Encarnacao
    Vilarica, Ana Sofia
    Alves, Paula
    Sotto-Mayor, Renato
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [42] Use of thyroid transcription factor-1 (TTF-1) to differentiate between primary and metastatic adenocarcinoma on FNA biopsy of lung
    Khetani, K
    Anand, N
    Mandich, D
    Cartun, RW
    Voytek, T
    LABORATORY INVESTIGATION, 2001, 81 (01) : 54A - 54A
  • [43] Use of thyroid transcription factor-1 (TTF-1) to differentiate between primary and metastatic adenocarcinoma on FNA biopsy of lung
    Khetani, K
    Anand, N
    Mandich, D
    Cartun, RW
    Voytek, T
    MODERN PATHOLOGY, 2001, 14 (01) : 54A - 54A
  • [44] Thyroid transcription factor-1 (TTF-1) distinguishes mesothelioma from pulmonary adenocarcinoma
    Anwar, F
    Schmidt, RA
    LABORATORY INVESTIGATION, 1999, 79 (01) : 181A - 181A
  • [45] Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations
    Park, Ji Young
    Jang, Seung Hun
    Kim, Hwan Il
    Kim, Joo-Hee
    Park, Sunghoon
    Hwang, Yong Il
    Jung, Ki-Suck
    Seo, Jinwon
    Lee, Chang Youl
    Ko, Yousang
    Park, Yong-Bum
    BMC CANCER, 2019, 19 (1)
  • [46] Thyroid transcription factor-1 and matrix metal loproteinase-9 in the prognostic assessment of patients with lung adenocarcinoma.
    Martins, SJ
    Ho, N
    Capelozzi, VL
    Takagaki, TY
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 672S - 672S
  • [47] Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations
    Ji Young Park
    Seung Hun Jang
    Hwan Il Kim
    Joo-Hee Kim
    Sunghoon Park
    Yong Il Hwang
    Ki-Suck Jung
    Jinwon Seo
    Chang Youl Lee
    Yousang Ko
    Yong-Bum Park
    BMC Cancer, 19
  • [48] Prognostic assessment of patients with lung adenocarcinoma: Immunohistochemical expression of thyroid transcription factor-1 and matrix metalloproteinase-9
    Martins, S
    Takagaki, T
    Ho, N
    Capelozzi, V
    LUNG CANCER, 2005, 49 : S293 - S293
  • [49] Thyroid Transcription Factor-1 Expression Correlates with Predominant Histologic Subtypes and Recurrence in Stage I Lung Adenocarcinoma Patients
    Kadota, K.
    Nitadori, J-i
    Suzuki, K.
    Sima, C. S.
    Yoshizawa, A.
    Rusch, V. W.
    Travis, W. D.
    Adusumilli, P. S.
    MODERN PATHOLOGY, 2012, 25 : 479A - 479A
  • [50] Thyroid transcription factor-1 may be expressed in ductal adenocarcinoma of the prostate: a potential pitfall
    Lim, Tony Kiat-Hon
    Teo, Clarence
    Giron, Danilo M.
    Chong, Yew-Lam
    Cheng, Christopher
    Tan, Puay-Hoon
    JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (08) : 941 - 943